GlassScriptPhysician profile
Lillian Burke
NPI 1033101670
$1,897.44
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,658 · 2024: $240.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,897.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,897.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $284.31 | 2023 | |
| Amgen INC. | $156.26 | 2023 | Nplate, Xgeva, Blincyto |
| Blueprint Medicines Corporation | $139.12 | 2023-2024 | Ayvakit |
| Genentech USA, INC. | $136.77 | 2023 | Lunsumio, Gavreto, Tecentriq |
| Kite Pharma, INC. | $123.50 | 2023 | |
| Pharming Healthcare, INC. | $114.59 | 2023 | Joenja |
| Janssen Scientific Affairs, LLC | $114.30 | 2023 | Rybrevant, Balversa, Tecvayli |
| Beigene USA, INC. | $113.35 | 2023 | Brukinsa |
| Cti Biopharma Corp. | $112.16 | 2023 | Vonjo |
| Agios Pharmaceuticals, INC. | $111.44 | 2023 | Pyrukynd |
| Pharmacyclics LLC, An Abbvie Company | $105.17 | 2023 | Imbruvica |
| Genzyme Corporation | $100.74 | 2023 | |
| Pfizer INC. | $96.00 | 2024 | |
| Janssen Biotech, INC. | $91.40 | 2023 | Tecvayli, Carvykti, Darzalex |
| Pharmacosmos Therapeutics INC. | $44.96 | 2023-2024 | Monoferric |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Morphosys, US INC. | $35.39 | 2023 | Monjuvi |
| Abbvie INC. | $17.98 | 2023 | Venclexta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lillian Burke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.